Rapid answers for life-saving treatment

MedicQuant has invented the first-in-class technology to measure small molecule drug concentrations in whole blood at the point-of-care.
The breakthrough platform technolology will enable life-saving therapies and be a critical tool for precision medicine.

Our first product focuses on point-of-care testing for Direct Oral Anticoagulants (DOACs) in emergency setting, designed to save lives and improve healthcare efficiency.

Need is expressed by Key Opinion Leaders in the field

It would be very impactful if DOAC drug levels were available at the point-of-care in 10 minutes.

‍

Feedback from the US, Director of Hemophilia and Thrombosis

DOAC levels are the only thing we wait for currently before thrombolysis. A point-of-care DOAC test could be a game changer in acute stroke treatment.

‍

Feedback from the UK, Consultant Neurologist, Hyper-acute stroke unit

The only thing we wait for is the DOAC levels in order to treat stroke patients on DOACs. We need a rapid test for DOACs, today rather than tomorrow.

Feedback from DK, Chief physician, Department of Neurology

Technology

Lab-grade diagnostics in under 10 minutes

MedicQuant is a spin-out from the Gothelf Lab at iNANO, Aarhus University, Denmark, and stands on the foundation of more than 11 years of state-of-the-art research. Our innovative technology is built on the proprietary, patent-pending platform using DNA nanotechnology, designed for precise measurement of small molecules. This innovative system delivers diagnostic accuracy comparable to laboratory standards in just 10 minutes directly from a whole blood sample.

While the assays are currently being developed for anticoagulants, the platform allows for easy adaptation to other small molecules. We have already demonstrated proof of concept for antibiotics, anticancer drugs, and antirheumatic drugs, among others.
‍
The novel cartridge system, also patent-pending, generates signals with minimal user handling and can process complex media such as whole blood. Usability studies conducted with end users at relevant sites have rated the system as "easy" or "very easy" to use.

Flow-front immunoassay

The disposable MedicQuant cartridge combines several laboratory steps in a single, self-contained format known as a flow-front immunoassay. It contains a blood-separation filter and two dried assay reagents positioned sequentially on a glass-fibre strip.

When a blood sample is added, the red blood cells are retained while the plasma moves through the cartridge by capillary action.

As the plasma front advances, it reconstitutes the reagents in a defined order: first the antibody-based recognition component, followed by the fluorescently labelled analyte analogue. The resulting reaction mixture is then drawn into the readout area, where the optical signal is measured directly.

Fluorescence readout

The readout is based on FRET, a distance-dependent transfer of energy between two fluorescent dyes.

At low drug concentrations, the labelled analyte analogue binds to the antibody, bringing the Cy3 donor (D) and Cy5 acceptor (A) into close proximity and generating a strong FRET signal.

At higher drug concentrations, analyte molecules in the sample occupy more of the antibody-binding sites, preventing the labelled analogue from binding and reducing the signal.

The reader excites Cy3 and measures the emission from both dyes. The ratio between these signals provides a robust quantitative readout that can be translated into the drug concentration.

A Point-of-Care System for the Quantification of Small-Molecule Drugs in Blood,
‍ACS Sensors · Published 2 July 2026
DOI: 10.1021/acssensors.6c00741

Fast

Results in just 10 minutes enabling immediate decision-making

Point-of-care

Compact, reliable and easy-to-use in any emergency departments

Precise

Diagnostic accuracy comparable to laboratory standards

Invest in MedicQuant

We are currently fundraising

We are raising our second equity round, and looking for new investors to join our existing investors.
‍
Please contact us for investor deck and further information.

Backed by